Reporting antimicrobial susceptibilities and resistance phenotypes in Acinetobacter spp: a nationwide proficiency study
Authors:
- María TomásMaría Tomás
- Germán BouGBGermán Bou
- Álvaro PascualÁPÁlvaro Pascual
- Spanish Society Of Clinical Microbiology And Infectious Diseases (Seimc)S(Spanish Society Of Clinical Microbiology And Infectious Diseases (Seimc)
- Angels VilanovaAVAngels Vilanova
- Ana Bordes BenítezABAna Bordes Benítez
- Natalia Montiel Quezel-GuerrazNQNatalia Montiel Quezel-Guerraz
- Ana Isabel López CallejaACAna Isabel López Calleja
- Luis Otero GuerraLGLuis Otero Guerra
- Fernando Chaves SánchezFSFernando Chaves Sánchez
- 13 December 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (3) , 692-697
Abstract
To evaluate the proficiency of Spanish microbiology laboratories with respect to the antimicrobial susceptibility testing (AST) of Acinetobacter spp. Eight Acinetobacter spp. with different resistance mechanisms were sent to 48 Spanish centres which were asked to report: (i) the AST system used; (ii) MICs; (iii) breakpoints used (CLSI versus EUCAST); (iv) clinical category; and (v) resistance mechanisms inferred. Minor, major and very major errors (mE, ME and VME, respectively) were determined. The greatest percentages of discrepancies were: (i) by AST method: 18.5% Etest, 14.3% Vitek 2 and Sensititre; (ii) by breakpoints: 20.5% (CLSI) and 10.8% (EUCAST); and (iii) by antimicrobial agent: ampicillin/sulbactam (56.2% CLSI), minocycline (40.7% CLSI), tobramycin (38.7% CLSI, 16.8% EUCAST), imipenem (27.8% CLSI, 30.0% EUCAST) and meropenem (25.4% CLSI, 20.8% EUCAST). Categorical error rates: (i) by AST method ranged from 30.0% (Phoenix) to 100% (Sensititre and disc diffusion) for mE, 0.0% (Etest, Sensititre, disc diffusion) to 40% (Phoenix) for ME, and 0.0% (Sensititre and disc diffusion) to 30% (Phoenix) for VME; (ii) by breakpoints: mE (80.1% CLSI, 58.4% EUCAST), ME (3.5% CLSI, 12.4% EUCAST) and VME (16.4% CLSI, 29.2% EUCAST); and (iii) by antimicrobial agent: mE (100% levofloxacin/CLSI, 100% levofloxacin and meropenem/EUCAST), ME (35.3% colistin/CLSI, 25.0% colistin/EUCAST) and VME (64.7% colistin/CLSI, 86.7% gentamicin/EUCAST). Clinical microbiology laboratories must improve their ability to determine antimicrobial susceptibilities of Acinetobacter spp. isolates. Higher discrepancies using CLSI when compared with EUCAST are mainly due to mE and to a much lesser extent to ME or VME.Keywords
This publication has 26 references indexed in Scilit:
- The Clinical Characteristics, Carbapenem Resistance, and Outcome of Acinetobacter Bacteremia According to GenospeciesPLOS ONE, 2013
- Comparison of the Vitek 2, MicroScan, and Etest Methods with the Agar Dilution Method in Assessing Colistin Susceptibility of Bloodstream Isolates of Acinetobacter Species from a Korean University HospitalJournal of Clinical Microbiology, 2013
- Cation Concentration Variability of Four Distinct Mueller-Hinton Agar Brands Influences Polymyxin B Susceptibility ResultsJournal of Clinical Microbiology, 2012
- Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in Acinetobacter baumanniiInternational Journal of Antimicrobial Agents, 2012
- Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilliJournal of Antimicrobial Chemotherapy, 2011
- Carbapenem Susceptibility Testing Errors Using Three Automated Systems, Disk Diffusion, Etest, and Broth Microdilution and Carbapenem Resistance Genes in Isolates of Acinetobacter baumannii-calcoaceticus ComplexAntimicrobial Agents and Chemotherapy, 2011
- Influence of different Mueller–Hinton agars and media age on Etest susceptibility testing of tigecyclineDiagnostic Microbiology and Infectious Disease, 2010
- Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, Microscan WalkAway, Vitek 2); high error rates with Microscan WalkAwayBMC Infectious Diseases, 2009
- Acinetobacter baumannii : Emergence of a Successful PathogenClinical Microbiology Reviews, 2008
- False extended-spectrum -lactamase detection in Acinetobacter spp. due to intrinsic susceptibility to clavulanic acidJournal of Antimicrobial Chemotherapy, 2007